Investment View
MST values Recce Pharmaceuticals at A$441m or A$2.54 per share on an undiluted basis, versus a bear case of A$1.85 per share, using a risk-adjusted net present value (rNPV) method and including A$22.9m in cash as at 31 March 2021.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.010(3.33%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.0¢ | $25.76K | 82.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13550 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18938 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |